Opportunity Information: Apply for RFA AI 14 003
Apply for RFA AI 14 003
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Consortium for Food Allergy Research (U19)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Feb 26, 2014 and posted on Feb 26, 2014.
- Applicants must submit their applications by Jun 19, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $6,100,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Independent school districts Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses State governments County governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Consortium for Food Allergy Research (CoFAR) (U19) opportunity, Funding Opportunity Number RFA-AI-14-003, is a National Institutes of Health (NIH) cooperative agreement designed to support a single lead institution that will run and coordinate a larger, multi-project, multi-institution clinical research program. The central idea is that one applicant organization serves as the administrative and scientific hub for CoFAR, taking responsibility not only for conducting high-impact clinical studies but also for providing the leadership, governance, and day-to-day coordination needed to keep a complex consortium functioning smoothly across multiple participating sites. Because this is a cooperative agreement, the expectation is an active partnership between the awardee and NIH, with substantial NIH involvement typical of U19 mechanisms.
The program focus is squarely on improving prevention and treatment strategies for food allergy by studying immune-based and other interventions. The scope explicitly includes severe food-allergen-associated allergic reactions and anaphylaxis, as well as food-allergen-associated eosinophilic esophagitis. Rather than limiting the work to one type of study, the FOA calls for a comprehensive clinical research portfolio that combines interventional trials with associated mechanistic studies, along with observational and natural history and/or genetics studies, also paired with mechanistic components. The mechanistic emphasis signals that CoFAR is not just meant to test whether an intervention works, but to dig into why it works (or fails), how immune pathways are altered, and what underlying biology drives different patient outcomes. Overall, the goal is to advance understanding of immunopathogenesis in these conditions while simultaneously generating evidence that can translate into better clinical prevention and treatment approaches.
In terms of funding and scale, the FOA anticipated a single award (ExpectedAwards: 1) with an estimated total funding level of $6,100,000. It falls under the Health activity category and is linked to CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). There is no cost sharing or matching requirement, which lowers barriers for applicants that might otherwise struggle to provide institutional matching funds. Key dates included a posted and creation date of February 26, 2014, an original and current closing date of June 19, 2014, and an archive date of July 20, 2014.
Eligibility is broad across U.S.-based organizations and includes many government entities (state, county, city/township, special district governments), public and state controlled institutions of higher education, private institutions of higher education, nonprofit organizations (both 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations other than small businesses, small businesses, independent school districts, public housing authorities/Indian housing authorities, and several categories of tribal governments and tribal organizations. The FOA also explicitly lists eligibility for a range of mission-specific institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and U.S. territories or possessions. At the same time, the announcement makes clear that non-U.S. entities (foreign institutions) are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. However, it allows “foreign components†as defined in the NIH Grants Policy Statement, which generally means limited, well-justified foreign elements may be included when they add unique scientific value, even though the applicant organization itself must be eligible and based in the U.S.
Operationally, applicants were expected to propose a structure capable of administering a consortium: coordinating multiple projects, managing multi-site clinical research, and ensuring the integration of clinical trials, observational work, and mechanistic laboratory studies. Since the award is meant to “continue the mission of the CoFAR,†proposals would be expected to show a clear plan for sustaining and advancing the consortium model, including consistent protocols across sites, strong data and safety oversight appropriate for interventional trials, and a cohesive strategy for linking clinical outcomes to mechanistic and potentially genetic insights. The full announcement was made available through an NIH grants link (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-003.html), with NIH Office of Extramural Research (OER) webmaster contacts provided for access or linking issues.
FAQs: Consortium for Food Allergy Research (CoFAR) (U19) - RFA-AI-14-003
What is this funding opportunity?
This is a National Institutes of Health (NIH) cooperative agreement opportunity to support the Consortium for Food Allergy Research (CoFAR) using the U19 mechanism. It is identified as Funding Opportunity Number (FON) RFA-AI-14-003.
What does it mean that this is a cooperative agreement (U19)?
A cooperative agreement indicates an active partnership between the awardee and NIH, with substantial NIH involvement expected as part of the award. The funded organization is not operating independently in the way a typical grant might; NIH is expected to be actively engaged in the program consistent with U19 mechanisms.
How many awards were expected?
The funding opportunity anticipated a single award (ExpectedAwards: 1).
How much funding was anticipated under this opportunity?
The estimated total funding level was $6,100,000.
What is the overall purpose of CoFAR under this FOA?
The purpose is to support a single lead institution that will run and coordinate a larger, multi-project, multi-institution clinical research program focused on improving prevention and treatment strategies for food allergy. The lead institution serves as the administrative and scientific hub for the consortium.
What kinds of research activities were expected to be included?
The FOA called for a comprehensive clinical research portfolio that combines:
- Interventional clinical trials paired with associated mechanistic studies
- Observational and natural history and/or genetics studies, also paired with mechanistic components
What does the FOA mean by emphasizing "mechanistic studies"?
The mechanistic emphasis means the program is not only meant to test whether an intervention works, but also to investigate why it works (or fails), how immune pathways are altered, and what underlying biology drives different patient outcomes.
What conditions or topics were within the scope of this FOA?
The scope focused on improving prevention and treatment strategies for food allergy by studying immune-based and other interventions. It explicitly included:
- Severe food-allergen-associated allergic reactions and anaphylaxis
- Food-allergen-associated eosinophilic esophagitis
Is the program limited only to clinical trials?
No. The FOA described a broad portfolio that includes interventional trials with mechanistic studies as well as observational, natural history, and/or genetics studies, also linked to mechanistic work.
What role is the lead institution expected to play?
The lead institution is expected to function as the administrative and scientific hub for CoFAR, taking responsibility for leadership, governance, and day-to-day coordination across multiple participating sites, while also conducting high-impact clinical studies.
Does the opportunity expect multi-site or multi-institution coordination?
Yes. The award is designed to support a multi-project, multi-institution clinical research program, coordinated by a single lead institution.
What kind of operational structure were applicants expected to propose?
Applicants were expected to propose a structure capable of administering a consortium, including coordinating multiple projects, managing multi-site clinical research, and ensuring integration across clinical trials, observational work, and mechanistic laboratory studies.
Was there an expectation to continue an existing consortium mission?
Yes. The FOA states that the award is meant to "continue the mission of the CoFAR," implying proposals should include a plan for sustaining and advancing the consortium model.
What types of oversight were implied for the clinical research activities?
The opportunity highlighted the need for strong oversight appropriate for interventional trials, including data and safety oversight, and consistent protocols across sites.
What is the activity category for this opportunity?
The activity category was Health.
Which CFDA programs were associated with this funding opportunity?
The FOA was linked to CFDA numbers:
- 93.855 (Allergy and Infectious Diseases Research)
- 93.856 (Microbiology and Infectious Diseases Research)
Is cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was broad across U.S.-based organizations and included many types of entities, such as:
- State, county, city/township, and special district governments
- Public and state controlled institutions of higher education
- Private institutions of higher education
- Nonprofit organizations (501(c)(3) and certain non-501(c)(3) entities)
- For-profit organizations other than small businesses
- Small businesses
- Independent school districts
- Public housing authorities/Indian housing authorities
- Tribal governments and tribal organizations
- U.S. territories or possessions
- Faith-based or community-based organizations
Were specific institution types explicitly listed as eligible?
Yes. The FOA explicitly listed eligibility for several mission-specific institution types, including:
- Historically Black Colleges and Universities (HBCUs)
- Hispanic-Serving Institutions
- Tribally Controlled Colleges and Universities
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
Are non-U.S. (foreign) institutions eligible to apply?
No. The announcement states that non-U.S. entities (foreign institutions) are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. The FOA states that non-U.S. components of U.S. organizations are not eligible.
Does the FOA allow any foreign involvement at all?
Yes. It allows "foreign components" as defined in the NIH Grants Policy Statement, meaning limited, well-justified foreign elements may be included when they add unique scientific value, even though the applicant organization must be eligible and based in the U.S.
What were the key dates for this opportunity?
- Posted/Created date: February 26, 2014
- Original closing date: June 19, 2014
- Current closing date: June 19, 2014
- Archive date: July 20, 2014
Is this opportunity still open?
No. Based on the listed closing date (June 19, 2014) and archive date (July 20, 2014), this FOA is archived and is not open for applications.
Where can the full official announcement be found?
The FOA referenced the NIH grants page for the full announcement at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-003.html
Who was listed for help with access or linking issues?
NIH Office of Extramural Research (OER) webmaster contacts were provided for access or linking issues, according to the opportunity description.
What is the central scientific goal of the program?
The central goal is to advance understanding of immunopathogenesis in food allergy-related conditions while generating evidence that can translate into better clinical prevention and treatment approaches.
Does the FOA specify the types of interventions to be studied?
It broadly describes immune-based and other interventions, without specifying particular products, agents, or modalities in the provided summary.
Does the FOA require integrating clinical outcomes with mechanistic or genetic insights?
Yes. The described scope and operational expectations emphasize linking clinical studies to mechanistic components and, where applicable, to natural history and/or genetics studies to better understand biological drivers of outcomes.
Browse more opportunities from the same category: Health
Next opportunity: Climate Monitoring and Reporting
Previous opportunity: FY 2014 Youth Leadership and Teacher Professional Development Program with Bosnia and Herzegovina
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 14 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 14 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Health Impact Assessment for Improved Community Design Apply for CDC RFA EH14 1407 Funding Number: CDC RFA EH14 1407 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $145,000 |
| Strengthening the National Institutes of Health in the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 115804CONT14 Funding Number: CDC RFA GH11 115804CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Strengthening Human Resources for Health through Continuing Education of Health Workers in the Federal Democratic Republic of Ethiopia under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 116704CONT14 Funding Number: CDC RFA GH11 116704CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Demographic Surveillance Study support in the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1110104CONT14 Funding Number: CDC RFA GH11 1110104CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Surveillance and Research of Muscular Dystrophies and Neuromuscular Disorders Apply for RFA DD 14 001 Funding Number: RFA DD 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Increasing the Capacity of the Government of Barbados to expand Coordinated HIV Prevention, Strategic Information, and Laboratory Programs under the Presidents Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 120403CONT14 Funding Number: CDC RFA GH12 120403CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Initiative for Maximizing Student Development (IMSD) (R25) Apply for PAR 14 121 Funding Number: PAR 14 121 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Health Surveillance through Networking, Regional Coordination and Strengthening of Technology, Communication and Training in Epidemiology to Improve Emergency Response in Publich Health under the International Health Regulations and the Hea Apply for CDC RFA GH10 100505CONT14 Funding Number: CDC RFA GH10 100505CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Alcohol Induced Effects on Tissue Injury and Repair (R21) Apply for PA 14 124 Funding Number: PA 14 124 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Alcohol Induced Effects on Tissue Injury and Repair (R01) Apply for PA 14 123 Funding Number: PA 14 123 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening Adherence to Antiretroviral Based HIV Treatment and Prevention (R21) Apply for PA 14 125 Funding Number: PA 14 125 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Strengthening Adherence to Antiretroviral Based HIV Treatment and Prevention (R01) Apply for PA 14 126 Funding Number: PA 14 126 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders Apply for CDC RFA DD14 1409 Funding Number: CDC RFA DD14 1409 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Targeted Basic Behavioral and Social Science and Intervention Development for HIV Prevention and Care (R01) Apply for PA 14 127 Funding Number: PA 14 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Targeted Basic Behavioral and Social Science and Intervention Development for HIV Prevention and Care (R21) Apply for PA 14 128 Funding Number: PA 14 128 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Improving Delivery of HIV Prevention and Treatment through Implementation Science and Translational Research (R21) Apply for PA 14 129 Funding Number: PA 14 129 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Accelerating Improvements in the HIV Care Continuum (R21) Apply for PA 14 130 Funding Number: PA 14 130 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Improving Delivery of HIV Prevention and Treatment through Implementation Science and Translational Research (R01) Apply for PA 14 131 Funding Number: PA 14 131 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Structural Level Interventions Through Enhanced Understanding of Social Determinants in HIV Prevention and Care (R01) Apply for PA 14 133 Funding Number: PA 14 133 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Structural Level Interventions Through Enhanced Understanding of Social Determinants in HIV Prevention and Care (R21) Apply for PA 14 134 Funding Number: PA 14 134 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 14 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.